flow trial semaglutide nejm kidney outcomes hazard ratio 0.76 2024 Semaglutides Are Poised to Remake Chronic Kidney Disease Care Notable Articles of 2024: FLOW

If you have completed four weeks at 0.25 mg without significant GI issues, stepping up to 0.5 mg is exactly what the clinical guidelines recommend

Pre-existing cardiac conditions : Ozempic may be prescribed to patients with established cardiovascular disease

Rao SAN, Krishnasamy SS

Over-the-counter topical GHK-Cu products can provide localized skin benefits

Any licensed dosing schedule would ultimately be defined by a future Summary of Product Characteristics (SmPC) if regulatory approval is granted

The statistical significance of the difference between two means assessed twice for the same research group was evaluated using a paired t-test or and Wilcoxon signed-rank test